论文部分内容阅读
目的探讨外周血癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)和神经元特异性烯醇化酶(NSE)的检测对肺癌的诊断、病理分型和疗效判断的临床用价值。方法采用化学发光法检测了62例肺癌患者、54例良性肺部疾病患者、36例健康人、40例肺癌患者手术前后血清CEA、CYFRA21-1和NSE的水平。结果肺癌患者手术前血清CEA、CYFRA21-1和NSE的含量明显高于良性肺部疾病组及正常对照组(P<0.01)。鳞癌组、腺癌组和小细胞癌组之间肿瘤标志物CEA、CYFRA21-1和NSE水平差异有统计学意义。CEA阳性率以腺癌组最高(84%),CYFRA21-1阳性率以鳞癌组最高(85.2%),NSE阳性率以小细胞癌组最高(80.0%)。手术治疗后未复发转移组CEA、CYFRA21-1和NSE水平低于术前,而复发转移组与术前比变化不显著(P>0.05)。结论血清CEA、CYFRA21-1和NSE的检测对不同病理类型肺癌患者的诊断、病情检测及疗效判断有较好的临床参考价值。
Objective To investigate the clinical value of detection of peripheral blood carcinoembryonic antigen (CEA), cytokeratin 19 (CYFRA21-1) and neuron-specific enolase (NSE) in the diagnosis, pathological typing and therapeutic efficacy of lung cancer. Methods The levels of serum CEA, CYFRA21-1 and NSE in 62 patients with lung cancer, 54 patients with benign lung disease, 36 healthy people and 40 patients with lung cancer before and after operation were measured by chemiluminescence method. Results The serum levels of CEA, CYFRA21-1 and NSE before operation in lung cancer patients were significantly higher than those in benign lung disease group and normal control group (P <0.01). The differences of CEA, CYFRA21-1 and NSE between squamous cell carcinoma, adenocarcinoma and small cell carcinoma were statistically significant. The positive rate of CEA in adenocarcinoma group was the highest (84%). The positive rate of CYFRA21-1 in squamous cell carcinoma group was the highest (85.2%). The positive rate of NSE was the highest in small cell carcinoma group (80.0%). The levels of CEA, CYFRA21-1 and NSE in the non-recurrence and metastasis group after operation were lower than those before operation, but the recurrence and metastasis in the recurrence and metastasis group were not significantly different (P> 0.05). Conclusion The detection of serum CEA, CYFRA21-1 and NSE has a good clinical value for diagnosis, disease detection and curative effect judgment of different pathological types of lung cancer patients.